Combination Therapy with Mogamulizumab and Pegylated Liposomal Doxorubicin in Tumoral Advanced-Stage Mycosis Fungoides/Sézary Syndrome: A Two-Case Report

Clicks: 8
ID: 332370
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #383 of 397 articles by views in the british journal of dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 397 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Two patients with advanced-stage mycosis fungoides/Sézary syndrome achieved deep blood responses with mogamulizumab, including peripheral blood MRD negativity, but developed progressive tumoral skin disease. The addition of pegylated liposomal doxorubicin resulted in rapid tumour regression while maintaining blood disease control. These cases highlight a compartment-directed therapeutic strategy and suggest complementary activity of both agents in advanced cutaneous T-cell lymphoma.
Reference Key
openalex_W7221820472 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Javier Gil‐Lianes, Andrea Combalía, Teresa Estrach, Magí Brufau‐Cochs, Inés Monge, Irene López‐Oreja, Pablo Mozas
Journal the british journal of dermatology
Year 2026
DOI
10.1093/bjd/ljag457
URL
https://doi.org/10.1093/bjd/ljag457
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.